Clinical Trial Update: Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant dose-dense chemotherapy for hormone receptor-positive, HER2-negative breast cancer with high proliferation index; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Shantou Central Hospital | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING